ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Acquired by Northern Trust Corp

Northern Trust Corp lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 5.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 478,153 shares of the company’s stock after acquiring an additional 25,773 shares during the period. Northern Trust Corp’s holdings in ARS Pharmaceuticals were worth $5,045,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of SPRY. KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $73,000. Compass Capital Corp MA ADV acquired a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at about $106,000. Teacher Retirement System of Texas purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $122,000. Amica Mutual Insurance Co. purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $151,000. Finally, PEAK6 LLC acquired a new stake in shares of ARS Pharmaceuticals during the fourth quarter worth about $162,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Down 0.8%

Shares of SPRY opened at $14.22 on Thursday. The company has a market capitalization of $1.40 billion, a price-to-earnings ratio of -27.88 and a beta of 0.84. ARS Pharmaceuticals, Inc. has a 52 week low of $7.55 and a 52 week high of $18.51. The stock’s 50-day moving average price is $13.48 and its 200-day moving average price is $12.88.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.35). The company had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million. As a group, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price objective on the stock. Finally, Scotiabank began coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They set a “sector outperform” rating and a $30.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $31.00.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the sale, the insider now directly owns 7,696 shares of the company’s stock, valued at approximately $107,744. This trade represents a 56.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,002 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now owns 210,346 shares of the company’s stock, valued at $2,587,255.80. This trade represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,602 shares of company stock worth $1,311,041 in the last three months. Company insiders own 33.50% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.